Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vera Mazurak

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Neuron|March 26, 2026
Lysosomal salvage of neuronal lipids enables glial infiltration of synaptic regionsEmma K Theisen, Irma Magaly Rivas-Serna, Peiwen Cheng, et al.
JHEP Reports : Innovation in Hepatology|August 14, 2025
Type II fibre atrophy and nuclear disruption in decompensated cirrhosisMaryam Motamedrad, Maryam Ebadi, Norberto Sanchez-Fernandez, et al.
International Journal of Cancer|June 9, 2025
Safety and efficacy of docosahexaenoic acid supplementation during neoadjuvant breast cancer therapy: Findings from the phase II, double-blind, randomized controlled DHA-WIN trialJaqueline Munhoz, Marnie Newell, Gilbert Bigras, et al.
BMJ Open|September 19, 2019
Comparing docosahexaenoic acid (DHA) concomitant with neoadjuvant chemotherapy versus neoadjuvant chemotherapy alone in the treatment of breast cancer (DHA WIN): protocol of a double-blind, phase II, randomised controlled trialMarnie Newell, John R Mackey, Gilbert Bigras, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Neuron|March 26, 2026
Lysosomal salvage of neuronal lipids enables glial infiltration of synaptic regionsEmma K Theisen, Irma Magaly Rivas-Serna, Peiwen Cheng, et al.
JHEP Reports : Innovation in Hepatology|August 14, 2025
Type II fibre atrophy and nuclear disruption in decompensated cirrhosisMaryam Motamedrad, Maryam Ebadi, Norberto Sanchez-Fernandez, et al.
International Journal of Cancer|June 9, 2025
Safety and efficacy of docosahexaenoic acid supplementation during neoadjuvant breast cancer therapy: Findings from the phase II, double-blind, randomized controlled DHA-WIN trialJaqueline Munhoz, Marnie Newell, Gilbert Bigras, et al.
BMJ Open|September 19, 2019
Comparing docosahexaenoic acid (DHA) concomitant with neoadjuvant chemotherapy versus neoadjuvant chemotherapy alone in the treatment of breast cancer (DHA WIN): protocol of a double-blind, phase II, randomised controlled trialMarnie Newell, John R Mackey, Gilbert Bigras, et al.
Pageof 4